Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang East-Asia Pharmaceutical Co Days Payable Chart
SHSE:605177 vs VRTX, REGN, RVMD: Days Payable Comparison
For the Biotechnology subindustry, Zhejiang East-Asia Pharmaceutical Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhejiang East-Asia Pharmaceutical Co Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zhejiang East-Asia Pharmaceutical Co's Days Payable distribution charts can be found below:
* The bar in red indicates where Zhejiang East-Asia Pharmaceutical Co's Days Payable falls into.
Zhejiang East-Asia Pharmaceutical Co Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zhejiang East-Asia Pharmaceutical Co (SHSE:605177) has a Days Payable of 153.20 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Zhejiang East-Asia Pharmaceutical Co and its competitors. This is near median its historical median of 162.65. Over the past decade, Zhejiang East-Asia Pharmaceutical Co's Days Payable has ranged from 100.40 to 279.94. According to the industry distribution chart, Zhejiang East-Asia Pharmaceutical Co ranks #250 out of 702 companies in the Biotechnology industry, placing it in the top 35.6%.
Is Zhejiang East-Asia Pharmaceutical Co's Days Payable too high?
Zhejiang East-Asia Pharmaceutical Co's current Days Payable of 153.20 is near median its 10-year median of 162.65. Over the past 10 years, this metric has ranged from a low of 100.40 to a high of 279.94. The Biotechnology industry median Days Payable is 113.10. Zhejiang East-Asia Pharmaceutical Co's value of 153.20 is 35.5% above this industry median. Based on the distribution chart, Zhejiang East-Asia Pharmaceutical Co ranks #250 out of 702 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Zhejiang East-Asia Pharmaceutical Co has a GF Score™ of 57/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Zhejiang East-Asia Pharmaceutical Co's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Zhejiang East-Asia Pharmaceutical Co ranks #250 out of 702 companies for Days Payable. This puts Zhejiang East-Asia Pharmaceutical Co in the upper half of its industry. The industry median Days Payable is 113.10. Zhejiang East-Asia Pharmaceutical Co's value of 153.20 is 35.5% above this benchmark. Historically, Zhejiang East-Asia Pharmaceutical Co's own Days Payable has ranged from 100.40 to 279.94 over the past decade. While the company's 10-year median is 162.65 vs. the industry median of 113.10, Zhejiang East-Asia Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.10, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zhejiang East-Asia Pharmaceutical Co's current Days Payable of 153.20 is 35.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Zhejiang East-Asia Pharmaceutical Co and its competitors. For the Biotechnology industry, the median Days Payable is 113.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhejiang East-Asia Pharmaceutical Co's current Days Payable is 153.20, which is near median its own 10-year median of 162.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang East-Asia Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang East-Asia Pharmaceutical Co (SHSE:605177) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥12.42, compared to a current price of ¥15.10 — trading 21.6% above its estimated fair value. The current Days Payable is 153.20, which is near median its 10-year median of 162.65 and 35.5% above the Biotechnology industry median of 113.10. Zhejiang East-Asia Pharmaceutical Co's overall GF Score™ is 57/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Zhejiang East-Asia Pharmaceutical Co (SHSE:605177), the current Days Payable is 153.20 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhejiang East-Asia Pharmaceutical Co (SHSE:605177) Overvalued in 2026?
Based on GuruFocus' analysis, Zhejiang East-Asia Pharmaceutical Co stock appears to be overvalued.
The current stock price of ¥15.10 is trading 21.6% above its estimated GF Value™ of ¥12.42.
GuruFocus considers Zhejiang East-Asia Pharmaceutical Co to be Modestly Overvalued.
Key valuation signals for SHSE:605177:
Days Payable: 153.20 (near median its 10-year median of 162.65)
GF Value™: ¥12.42 vs. price of ¥15.10 (21.6% above fair value)
Industry Position: 35.5% above the Biotechnology median (#250 of 702)
No single metric tells the full story. See the SHSE:605177 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhejiang East-Asia Pharmaceutical Co Business Description
Zhejiang East-Asia Pharmaceutical Co Ltd is mainly engaged in the production of bulk pharmaceutical chemicals, tablets, granules and capsules. The company's main products are: Ofloxacin, levofloxacin, loratadine hydrochloride, levofloxacin hydrochloride, trimebutine maleate, ketoconazole, terbinafine hydrochloride, piperazine, ticlazole and so on.
57GF Score
Get the complete analysis for SHSE:605177
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:605177 has been successfully added to your 
